Skip to main content

Table 3 Sensitivity analysis, total annual cost-of-illness (Euros, millions) of hypertension in the presence and absence of MetS; 2008

From: Epidemiological and economic burden of metabolic syndrome and its consequences in patients with hypertension in Germany, Spain and Italy; a prevalence-based model

  Germany Spain Italy
Baseline    
   Presence 24,427 1,908 4,877
   Absence 5,341 2,683 5,956
Type 2 diabetes; including only incident type 2 diabetes    
   Presence 8,753 1,050 1,775
   Absence 3,382 2,115 3,876
Proportion treated; assume 58% hypertensive subjects were treated in Spain    
   Presence NA 2,010 NA
   Absence NA 3,058 NA
Continuation rate; vary by 20% above/below the mean    
   + 20% Presence 24,418 1,913 4,895
   + 20% Absence 5,357 2,707 6,035
   - 20% Presence 24,406 1,898 4,850
   - 20% Absence 5,302 2,635 5,831
Costs; vary by 20% above/below the mean
Drug costs
   
   + 20% Presence 24,553 1,928 4,929
   + 20% Absence 5,423 4,329 6,147
   - 20% Presence 24,247 1,886 4,825
   - 20% Absence 5,224 2,603 5,762
CVD costs    
   + 20% Presence 25,481 2,049 5,041
   + 20% Absence 5,682 2,934 6,276
   - 20% Presence 23,373 1,769 4,714
   - 20% Absence 5,000 2,431 5,637
Type 2 diabetes costs    
   + 20% Presence 27,743 2,102 5,573
   + 20% Absence 5,735 2,803 6,392
   - 20% Presence 21,112 1,715 4,183
   - 20% Absence 4,948 2,564 5,521